Kymera lures Takeda SVP to be chief operating officer

22 May 2023

US clinical-stage biotech Kymera Therapeutics (Nasdaq: KYMR) today announced the appointment of Jeremy Chadwick as its chief operating officer (COO).

Dr Chadwick joins Kymera with extensive experience overseeing global development operations, regulatory and program management at a range of biopharmaceutical companies. As a member of the Company’s senior management team, Dr Chadwick will develop and execute near-term and long-range strategies to maximize the impact of Kymera’s expanding pipeline.

Prior to Kymera, Dr Chadwick served as senior vice president, Head of Global Development Office at Japanese pharma giant Takeda Pharmaceuticals (TYO: 4502), where his responsibilities included head of global regulatory affairs, as well as managing global drug safety, global clinical supply chain and several groups supporting global development operations.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK